CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 73 filers reported holding CONCERT PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,057,999 | +36.6% | 523,630 | +56.7% | 0.00% | 0.0% |
| Q3 2022 | $2,238,000 | +183.7% | 334,079 | +78.2% | 0.00% | – |
| Q2 2022 | $789,000 | +1417.3% | 187,488 | +1088.7% | 0.00% | – |
| Q3 2021 | $52,000 | -86.9% | 15,773 | -83.3% | 0.00% | – |
| Q2 2021 | $398,000 | +16.4% | 94,272 | +37.5% | 0.00% | – |
| Q1 2021 | $342,000 | -80.4% | 68,585 | -50.3% | 0.00% | – |
| Q4 2020 | $1,746,000 | +735.4% | 138,128 | +549.1% | 0.00% | – |
| Q3 2020 | $209,000 | +10.6% | 21,281 | +11.7% | 0.00% | – |
| Q2 2020 | $189,000 | -48.6% | 19,044 | -54.2% | 0.00% | – |
| Q1 2020 | $368,000 | -19.5% | 41,610 | -16.0% | 0.00% | – |
| Q4 2019 | $457,000 | +97.0% | 49,530 | +25.5% | 0.00% | – |
| Q3 2019 | $232,000 | -26.6% | 39,457 | +50.0% | 0.00% | – |
| Q2 2019 | $316,000 | -39.2% | 26,313 | -38.9% | 0.00% | – |
| Q1 2019 | $520,000 | +182.6% | 43,070 | +193.7% | 0.00% | – |
| Q4 2018 | $184,000 | -89.6% | 14,666 | -87.7% | 0.00% | – |
| Q3 2018 | $1,763,000 | -16.5% | 118,814 | -5.3% | 0.00% | -100.0% |
| Q2 2018 | $2,112,000 | +1.1% | 125,495 | +37.6% | 0.00% | 0.0% |
| Q1 2018 | $2,089,000 | -18.3% | 91,202 | -7.7% | 0.00% | 0.0% |
| Q4 2017 | $2,556,000 | +414.3% | 98,786 | +193.1% | 0.00% | – |
| Q3 2017 | $497,000 | +110.6% | 33,700 | +99.3% | 0.00% | – |
| Q2 2017 | $236,000 | -57.2% | 16,905 | -47.7% | 0.00% | – |
| Q1 2017 | $552,000 | +302.9% | 32,349 | +143.2% | 0.00% | – |
| Q4 2016 | $137,000 | -19.9% | 13,303 | -21.3% | 0.00% | – |
| Q3 2016 | $171,000 | +22.1% | 16,904 | +35.9% | 0.00% | – |
| Q2 2016 | $140,000 | -36.1% | 12,434 | +6.5% | 0.00% | – |
| Q3 2015 | $219,000 | -45.4% | 11,679 | -56.7% | 0.00% | – |
| Q2 2015 | $401,000 | +5.2% | 26,956 | +7.3% | 0.00% | – |
| Q1 2015 | $381,000 | +46.5% | 25,124 | +28.8% | 0.00% | – |
| Q4 2014 | $260,000 | -62.3% | 19,511 | -64.3% | 0.00% | – |
| Q3 2014 | $689,000 | +19.0% | 54,631 | -4.7% | 0.00% | – |
| Q2 2014 | $579,000 | -35.9% | 57,345 | -14.6% | 0.00% | – |
| Q1 2014 | $903,000 | – | 67,145 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |